NASDAQ:PRTK
Delisted
Paratek Pharmaceuticals Stock News
$2.23
+0 (+0%)
At Close: Dec 19, 2023
Paratek Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
08:05pm, Monday, 16'th May 2022 GlobeNewswire Inc.
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sav
Paratek Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
04:05pm, Monday, 16'th May 2022
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savin
Paratek Pharmaceuticals (PRTK) Q1 2022 Earnings Call Transcript
04:30pm, Thursday, 05'th May 2022 The Motley Fool
PRTK earnings call for the period ending March 31, 2022.
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q1 2022 Results - Earnings Call Transcript
10:27pm, Wednesday, 04'th May 2022
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Evan Loh - CEO Sarah Higgins - Vice President Finance Controller Adam Woodrow
Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million
08:05pm, Wednesday, 04'th May 2022 GlobeNewswire Inc.
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.9 Million from the Core Commercial Business, a 51% Increase over First Quarter 2021
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
08:05pm, Monday, 02'nd May 2022 GlobeNewswire Inc.
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sav
Paratek Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022
08:05pm, Tuesday, 26'th Apr 2022 GlobeNewswire Inc.
BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, May 4 at 4:3
Paratek Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022
04:05pm, Tuesday, 26'th Apr 2022
BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, May 4 at 4:30
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
08:05pm, Friday, 01'st Apr 2022 GlobeNewswire Inc.
BOSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-s
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q4 2021 Results - Earnings Call Transcript
05:02pm, Monday, 14'th Mar 2022 Seeking Alpha
Paratek Pharmaceuticals (PRTK) Q4 2021 Earnings Call Transcript
04:30pm, Monday, 14'th Mar 2022 The Motley Fool
PRTK earnings call for the period ending December 31, 2021.
Paratek Pharmaceuticals (PRTK) Q4 2021 Earnings Call Transcript
04:30pm, Monday, 14'th Mar 2022 The Motley Fool
PRTK earnings call for the period ending December 31, 2021.
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q4 2021 Results - Earnings Call Transcript
01:02pm, Monday, 14'th Mar 2022
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q4 2021 Results - Earnings Call Transcript
Paratek Pharmaceuticals: Q4 Earnings Insights
12:11pm, Monday, 14'th Mar 2022 Benzinga
Paratek Pharmaceuticals (NASDAQ: PRTK ) reported its Q4 earnings results on Monday, March 14, 2022 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Paratek Pharmaceuticals missed estimated earnings by 56.1%, reporting an EPS of $-0.64 versus … Full story available on Benzinga.com
Paratek Pharmaceuticals GAAP EPS of -$1.22 misses by $0.31, revenue of $130.16M misses by $3.57M
11:34am, Monday, 14'th Mar 2022 Seeking Alpha
Paratek Pharmaceuticals press release (PRTK): FY GAAP EPS of -$1.22 misses by $0.31.Revenue of $130.16M (+177.4% Y/Y) misses by $3.57M.
